Ferrier C M, de Witte H H, Straatman H, van Tienoven D H, van Geloof W L, Rietveld F J, Sweep C G, Ruiter D J, van Muijen G N
Department of Pathology, University Hospital Nijmegen, The Netherlands.
Br J Cancer. 1999 Mar;79(9-10):1534-41. doi: 10.1038/sj.bjc.6690245.
Enzyme-linked immunosorbent assay (ELISA) methods and immunohistochemistry (IHC) are techniques that provide information on protein expression in tissue samples. Both methods have been used to investigate the impact of the plasminogen activation (PA) system in cancer. In the present paper we first compared the expression levels of uPA, tPA, PAI-1 and uPAR in a compound group consisting of 33 cancer lesions of various origin (breast, lung, colon, cervix and melanoma) as quantitated by ELISA and semi-quantitated by IHC. Secondly, the same kind of comparison was performed on a group of 23 melanoma lesions and a group of 28 breast carcinoma lesions. The two techniques were applied to adjacent parts of the same frozen tissue sample, enabling the comparison of results obtained on material of almost identical composition. Spearman correlation coefficients between IHC results and ELISA results for uPA, tPA, PAI-1 and uPAR varied between 0.41 and 0.78, and were higher for the compound group and the breast cancer group than for the melanoma group. Although a higher IHC score category was always associated with an increased median ELISA value, there was an overlap of ELISA values from different scoring classes. Hence, for the individual tumour cases the relation between ELISA and IHC is ambiguous. This indicates that the two techniques are not directly interchangeable and that their value for clinical purposes may be different.
酶联免疫吸附测定(ELISA)方法和免疫组织化学(IHC)是能够提供组织样本中蛋白质表达信息的技术。这两种方法都已被用于研究纤溶酶原激活(PA)系统在癌症中的作用。在本文中,我们首先比较了由33个不同来源(乳腺癌、肺癌、结肠癌、宫颈癌和黑色素瘤)的癌症病灶组成的复合组中尿激酶型纤溶酶原激活物(uPA)、组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制剂-1(PAI-1)和尿激酶型纤溶酶原激活物受体(uPAR)的表达水平,通过ELISA进行定量,通过IHC进行半定量。其次,对一组23个黑色素瘤病灶和一组28个乳腺癌病灶进行了同样的比较。这两种技术应用于同一冷冻组织样本的相邻部分,从而能够比较几乎相同组成的材料所获得的结果。uPA、tPA、PAI-1和uPAR的IHC结果与ELISA结果之间的Spearman相关系数在0.41至0.78之间,复合组和乳腺癌组的相关系数高于黑色素瘤组。尽管较高的IHC评分类别总是与ELISA中位数增加相关,但不同评分类别的ELISA值存在重叠。因此,对于个别肿瘤病例,ELISA和IHC之间的关系并不明确。这表明这两种技术不能直接互换,它们在临床应用中的价值可能不同。